Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 3314 of 6351
-
Can a beta-blocker help a common type of heart failure? new study investigates.
Disease control CompletedBeta-blockers improve clinical outcomes in heart failure and reduced ejection fraction (HFrEF); but not in those with preserved EF. Global longitudinal strain (GLS) is a prognostic factor independent of left ventricular ejection fraction (LVEF). In a retrospective with 1969 patie…
Phase 4 • Sponsor: Seoul National University Bundang Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Experimental immune cell therapy takes aim at childhood cancers
Disease control Recruiting nowThis is an open-label phase I dose-escalation study to evaluate the safety of partially human leukocyte antigen (HLA)-matched multi tumor-associated antigen-specific T cell (TAA-T) therapy following lymphodepleting conditioning with or without local tumor ablation for pediatric a…
Phase 1 • Sponsor: Children's National Research Institute • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a common blood pressure drug improve major surgery outcomes?
Disease control CompletedHemodynamic instability is frequent during surgery and intraoperative hypotension is associated with excess morbidity and excess mortality in high-risk patients. In major abdominal surgery the incidence of intraoperative hypotension remains high. For the past few years, some tea…
Phase 3 • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New dialysis filters aim to cut bleeding risk by reducing heparin use
Disease control Recruiting nowChronic kidney disease (CKD) results from the progressive and irreversible destruction of the kidneys. As of December 31, 2018, there were 89,692 people in France undergoing replacement therapy, including 49,271 (55%) on dialysis and 40,421 (45%) with a functioning kidney transpl…
Sponsor: CHU de Reims • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
15,000 patients to reveal hidden heart dangers of Same-Day surgery
Knowledge-focused Recruiting nowThe proportion of noncardiac surgeries performed as same-day surgery is increasing worldwide, with more complex surgeries being performed on higher risk patients in the outpatient setting. Little is known on the risk factors, incidence and prognosis of patients undergoing same-da…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Can a mindfulness app rewire Teens' brains to stop overthinking?
Knowledge-focused Recruiting nowA growing body of research implicates rumination as being a transdiagnostic risk factor involved in the development of depression and anxiety in youth. Critically, mindfulness meditation has shown significant promise in targeting rumination, and ultimately improving depressive an…
Sponsor: Mclean Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy targets nerve pain in rare blood cancers
Disease control OngoingIn this research study, is combining a new treatment acalabrutinib with a standard treatment, rituximab or other CD20 antibody, to determine whether this combination is safe and effective for participants with Immunoglobulin (Ig) M monoclonal gammopathy of undetermined significan…
Phase 2 • Sponsor: Shayna Sarosiek, MD • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New combo therapy for aggressive lymphoma enters safety testing
Disease control OngoingThis phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed to block a protein called Brut…
Phase 1 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill hopes to fight Hard-to-Treat cancers
Disease control CompletedThis is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and preliminary anti-tumor activity of IPG7236 administered orally as a single agent to patients with advanced solid tumors. The stud…
Phase 1/2 • Sponsor: Nanjing Immunophage Biotech Co., Ltd • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can kids with cancer stop antibiotics sooner? new trial investigates
Disease control CompletedThis randomised controlled trial will determine the non-inferiority of stopping empiric antibiotics prior to absolute neutrophil count (ANC) recovery (Early Stopping) versus stopping antibiotics upon ANC recovery (Standard of Care/ Late Stopping) , in children with cancer and hig…
Phase 4 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Lymphoma Patients' vaccine response under scrutiny
Knowledge-focused Stopped earlyThe specific immune response to SARS-CoV-2 includes a humoral response - specific IgM appearing 5 days after the onset of symptoms while IgG appears after 14 days - and a T lymphocyte component, with specific activated CD8 and CD4 T lymphocytes. Mortality from infection varies g…
Sponsor: Versailles Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Could a common numbing drug cut opioid use after liver surgery?
Symptom relief CompletedThis is a randomized double blinded placebo-controlled study, conducted in Lund, Sweden. Patients will be randomized in two groups, with a ratio of 1:1. The experimental arm will receive intravenous Lidocaine perioperatively, and the Control arm will receive placebo, i.e. normal …
Phase 2/3 • Sponsor: Lund University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC
-
New syringe design tested for common eye disease treatment
Disease control OngoingThe study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab, including: exudative age-related macular degeneration, diab…
Phase 3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can brain scans forecast stroke recovery?
Knowledge-focused Recruiting nowOur study aims to measure metabolic and functional parameters of the infarcted territory by multimodal cerebral MRI in patients diagnosed with unilateral proximal occlusion of the middle cerebral artery and treated by thrombectomy in order to correlate those parameters to clinica…
Sponsor: Poitiers University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Experimental combo for lung cancer shows promise but study cut short
Disease control Stopped earlyThis is a multicenter, open-label, single-arm Phase II study to evaluate anti-tumor efficacy and safety of NT-I7 in combination with atezolizumab in subjects with PD-L1-expressing (TPS ≥ 1%), metastatic (Stage IV) or locally advanced squamous or non-squamous NSCLC who have not re…
Phase 2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Can learning to cope help kids breathe easier?
Symptom relief CompletedUncontrolled asthma in school-aged children is a significant public health problem. Latino children living in low-income contexts are at increased risk for uncontrolled asthma compared to non-Latino white children, and stress is an unaddressed factor in this disparity. Therefore,…
Sponsor: Erin M Rodriguez • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
New oral diabetes drug shows promise in early safety trial
Disease control CompletedThe main purpose of this study is to learn about the side effects of LY3502970 when given to Japanese participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Your personal air quality report: a key to cleaner living?
Knowledge-focused CompletedPersonal exposure to air pollution results from the interaction of individual time-activity patterns with levels of air pollution that vary over time and space. The increasing use of personal monitors capable of measuring geo-located and real-time air pollution in epidemiologic s…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
New combo therapy for advanced breast cancer shows promise in early trial
Disease control CompletedThis is a multicenter, open-label, non-controlled, phase I study to investigate the tolerability and safety of ONO-4578 used in combination with standard-of-care letrozole and a CDK4/6 inhibitor (palbociclib or Abemaciclib) as first-line endocrine therapy in postmenopausal patien…
Phase 1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Phone therapy may lift mood in epilepsy patients
Symptom relief Recruiting nowThis is a two-arm randomized controlled trial to compare telephone-based depression self-management (UPLIFT) to telephone-based support groups (BOOST). A sample of 120 English- and Spanish-speaking people with epilepsy (PWE) with elevated depressive symptoms will be enrolled. Bot…
Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC